



(22) Date de dépôt/Filing Date: 1993/03/25

(41) Mise à la disp. pub./Open to Public Insp.: 1993/09/28

(45) Date de délivrance/Issue Date: 2004/06/01

(30) Priorité/Priority: 1992/03/27 (RM 92 A 000222) IT

(51) Cl.Int.⁶/Int.Cl.⁶ A61K 38/05, A61K 31/40

(72) Inventeur/Inventor:
CAVAZZA, CLAUDIO, IT

(73) Propriétaire/Owner:
SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE
S.P.A, IT

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : COMPOSITIONS PHARMACEUTIQUES CONTENANT DE LA L-CARNITINE OU DE LA L-CARNITINE
ACYLE COMBINÉE A UN INHIBITEUR DE L'ENZYME DE CONVERSION POUR LE TRAITEMENT DES MALADIES
CARDIOVASCULAIRES ET METHODE DE TRAITEMENT DES MALADIES CARDIOVASCULAIRES

(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING L-CARNITINE OR AN ACYL L-CARNITINE IN
COMBINATION WITH AN ACE-INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS AND A
METHOD FOR TREATING CARDIOVASCULAR DISORDERS

(57) **Abrégé/Abstract:**

Compositions containing (a) L-carnitine, an acyl L-carnite, or a pharmacologically acceptable salt thereof in combination with (b) an ACE-inhibiter are useful for treating cardiovascular disorders. Orally, parenterally, rectally or transdermally administrable pharmaceutical compositions in unit form contain from about 0.5 to about 2 g of L-carnitine, or an equimolar amount of an acyl L-carnitine or a pharmacologically acceptable salt thereof, and, e.g., from about 5 to about 20 mg of the ACE-inhibitor lisinopril.



ABSTRACT OF THE DISCLOSURE

Compositions containing (a) L-carnitine, an acyl
L-carnitine, or a pharmacologically acceptable salt thereof
in combination with (b) an ACE-inhibitor are useful for
5 treating cardiovascular disorders. Orally, parenterally,
rectally or transdermally administrable pharmaceutical
compositions in unit dosage form contain from about 0.5 to
about 2 g of L-carnitine, or an equimolar amount of an acyl
L-carnitine or a pharmacologically acceptable salt thereof,
10 and, e.g., from about 5 to about 20 mg of the ACE-inhibitor
lisinopril.

SGB\ds

